Drugs / Humanized CD19 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04532268 | Aug 2020 → Aug 2023 overdue | B-cell acute lymphoblastic leukemia | Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Humanized CD19 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04532268 ↗ |
| Known as | hCART19 | “We performed a clinical trial to determine the safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell (hCART19) for R/R B-ALL.” PMID 36808074 ↗ Feb 2023 |
| Modality | Cell therapy | “Chimeric antigen receptor T (CAR-T) cell therapy is highly effective in inducing complete remission in haematological malignancies.” PMID 37192741 ↗ May 2023 |
| Route | Intravenous | “Each subject receive humanized CD19 CAR-T cells by intravenous infusion” NCT04532268 ↗ |
| Target | CD19 | “We performed a clinical trial to determine the safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell (hCART19) for R/R B-ALL.” PMID 36808074 ↗ Feb 2023 |